Perseus Proteomics (4882.T) Stock Price

Perseus Proteomics Price

CLOSED
154.00
​
Market closed

Revenue at Perseus Proteomics has contracted by 9.6% per year over the past 8 years to 135.51 M JPY. For Perseus Proteomics, the net margin of -529.9% is up versus -832.8% a few years ago.

Perseus Proteomics stock price

Access this data via the Eulerpool API

Perseus Proteomics business model & stock analysis

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 24 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Frequently asked questions about Perseus Proteomics

5 analysts currently rate the Perseus Proteomics stock: 4 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Perseus Proteomics share trades at 0.87 EUR (154.00 JPY).

The revenue of Perseus Proteomics is 135.51 M JPY. This figure is based on current financial data and reflects the company's business performance.

The profit of Perseus Proteomics is -718.11 M JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Perseus Proteomics is currently -3.67. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Perseus Proteomics stock.

The price-to-sales ratio (P/S) of Perseus Proteomics is currently 19.43. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Perseus Proteomics stock.

The Eulerpool Quality Score for Perseus Proteomics is 3/10.

The ISIN of Perseus Proteomics is JP3836800007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Perseus Proteomics is 4882.T. The ticker symbol is used to trade Perseus Proteomics shares on the stock exchange.

Fair ValueTerminal
155.54 JPY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
5.65 M JPY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website ppmx.com
Country
Currency
JPY
Initial public offering
Jun 22, 2021
ISIN
JP3836800007
Cusip
J63676118
Market capitalization
2.62 B JPYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-2.48
P/Ee 2028
-11.65
P/Ee 2029
—
P/Ee 2030
—
P/Se
21.94
EV/EBIT
—
P/B Ratio
2.15
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-58.97 %
Last updated Oct 13, 2026, 2:20 PM

Perseus Proteomics Peer Group

Perseus Proteomics FIGI

4882:JP · BBG000BCLPX54882:JT · BBG00RRMSB254882:JJ · BBG00RRMSBC44882:JE · BBG00RRMSBG04882:JI · BBG00RRMSBH94882:JU · BBG00RRMSBJ74882:JW · BBG00RRMSBK54882:JV · BBG0193R7BP7